Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 8

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Effects of lovastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by lovastatin

Hong, Soon-Pyo, Yang, Joon-Seung, Han, Jung-Yeon, Ha, Sung-Il, Chung, Joong-Wha, Koh, Young-Youp, Chang, Kyong-Sig, Choi, Dong-Hyun·2011·Journal of Pharmacy and Pharmacology
DOI 10.1111/j.2042-7158.2010.01160.x
Open this paper in CoChat — free account

Abstract

Objectives: The purpose of this study was to examine the effects of lovastatin on cytochrome P450 (CYP) 3A4 and P-glycoprotein (P-gp) in vitro and then to determine the effects of lovastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats. Methods: The pharmacokinetic parameters of diltiazem and desacetyldiltiazem were determined after orally administering diltiazem (12 mg/kg) to rats in the presence and absence of lovastatin (0.3 and 1.0 mg/kg). The effect of lovastatin on P-gp as well as CYP3A4 activity was also evaluated. Key findings: Lovastatin inhibited CYP3A4 enzyme activity with a 50% inhibition concentration of 6.06 µM. In addition, lovastatin significantly enhanced the cellular accumulation of rhodamine-123 in MCF-7/ADR cells overexpressing P-gp. Compared with the control (given diltiazem alone), the presence of lovastatin significantly altered the pharmacokinetic parameters of diltiazem. The areas under the plasma concentration–time curve (AUC) and the peak concentration of diltiazem were significantly increased (P < 0.05, 1.0 mg/kg) in the presence of lovastatin. Consequently, the absolute bioavailability values of diltiazem in the presence of lovastatin (11.1% at 1.0 mg/kg) were significantly higher (P < 0.05) than that of the control group (7.6%). The metabolite–parent AUC ratio in the presence of lovastatin (1.0 mg/kg) was significantly (P < 0.05) decreased compared with the control group. Conclusions: It might be considered that lovastatin resulted in reducing the first-pass metabolism in the intestine and/or in the liver via inhibition of CYP3A4 and increasing the absorption of diltiazem in the intestine via inhibition of P-gp by lovastatin.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.2042-7158.2010.01160.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 38

  1. Chaffman, 1985, Diltiazem: a review of its pharmacological properties and therapeutic efficacy, Drugs, 29, 387, 10.2165/00003495-198529050-00001 · DOI · Paper page
  2. Weir, 1995, Diltiazem: ten years of clinical experience in the treatment of hypertension, J Clin Pharmacol, 35, 220, 10.1002/j.1552-4604.1995.tb04051.x · DOI
  3. Yeung, 1993, Pharmacokinetics and metabolism of diltiazem in healthy males and females following a single oral dose, Eur J Drug Metab Pharmacokinet, 18, 199, 10.1007/BF03188796 · DOI
  4. Buckley, 1990, Diltiazem: a reappraisal of its pharmacological properties and therapeutic use, Drugs, 39, 757, 10.2165/00003495-199039050-00009 · DOI
  5. Narita, 1986, Hypotensive response of spontaneously hypertensive rats to centrally administered diltiazem and its metabolites: in relevance to the hypotensive action by oral administration, J Pharmacobiodyn, 9, 547, 10.1248/bpb1978.9.547 · DOI
  6. Yeung, 1998, Pharmacokinetics and hypotensive effect of diltiazem in rabbits: comparison of diltiazem with its major metabolites, J Pharm Pharmacol, 50, 1247, 10.1111/j.2042-7158.1998.tb03341.x · DOI
  7. Pichard, 1990, Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem, Drug Metab Dispos, 18, 711, 10.1016/S0090-9556(25)08637-4 · DOI
  8. Watkins, 1987, Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man, J Clin Invest, 80, 1029, 10.1172/JCI113156 · DOI · Paper page
  9. Kolars, 1992, Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia, Gastroenterology, 102, 1186, 10.1016/0016-5085(92)90756-O · DOI
  10. Lefebvre, 1996, First-pass metabolism of diltiazem in anesthetized rabbits: role of extrahepatic organs, Pharm Res, 13, 124, 10.1023/A:1016097805003 · DOI
  11. Homsy, 1995, The site of absorption in the small intestine determines diltiazem bioavailability in the rabbit, Pharm Res, 12, 1722, 10.1023/A:1016217822770 · DOI
  12. Homsy, 1995, Metabolism of diltiazem in hepatic and extrahepatic tissues of rabbits: in vitro studies, Pharm Res, 12, 609, 10.1023/A:1016226601988 · DOI
  13. Lee, 1991, Pharmacokinetics of diltiazem and deacetyldiltiazem in rats, Int J Pharm, 76, 71, 10.1016/0378-5173(91)90345-O · DOI
  14. Gottesman, 1993, Biochemistry of multidrug resistance mediated by the multidrug transporter, Annu Rev Biochem, 62, 385, 10.1146/annurev.bi.62.070193.002125 · DOI · Paper page
  15. Gan, 1996, CYP3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells: interaction between the two biochemical barriers to intestinal transport, Drug Metab Dispos, 24, 344, 10.1016/S0090-9556(25)07353-2 · DOI
  16. Wacher, 1998, Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics, J Pharm Sci, 87, 1322, 10.1021/js980082d · DOI · Paper page
  17. Wacher, 2001, Active secretion and enterocytic drug metabolism barriers to drug absorption, Adv Drug Deliv Rev, 46, 89, 10.1016/S0169-409X(00)00126-5 · DOI
  18. Ito, 1999, Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption theoretical approach, Pharm Res, 16, 225, 10.1023/A:1018872207437 · DOI
  19. Kubota, 2004, Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors, Biochem Pharmacol, 12, 2175, 10.1016/j.bcp.2004.02.037 · DOI
  20. Tobert, 2003, Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors, Nat Rev Drug Discov, 2, 517, 10.1038/nrd1112 · DOI · Paper page
  21. Khandwala, 2006, Lipid lowering inefficacy of high-dose statin therapy due to concurrent use of phenytoin, South Med J, 99, 1385, 10.1097/01.smj.0000251470.39036.ea · DOI
  22. Halpin, 1993, Biotransformation of lovastatin. V. Species differences in in vivo metabolite profiles of mouse, rat, dog, and human, Drug Metab Dispos, 21, 1003, 10.1016/S0090-9556(25)08192-9 · DOI
  23. Wang, 2001, HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein, Pharm Res, 18, 800, 10.1023/A:1011036428972 · DOI
  24. Mousa, 2000, The interaction of diltiazem with simvastatin, Clin Pharmacol Ther, 67, 267, 10.1067/mcp.2000.104609 · DOI
  25. Azie, 1998, The interaction of diltiazem with lovastatin and pravastatin, Clin Pharmacol Ther, 64, 369, 10.1016/S0009-9236(98)90067-4 · DOI
  26. Goebel, 1985, High performance liquid chromatographic determination of diltiazem and four of its metabolite in plasma, J Chromatogr, 345, 355, 10.1016/0378-4347(85)80172-9 · DOI
  27. Crespi, 1997, Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450, Anal Biochem, 248, 188, 10.1006/abio.1997.2145 · DOI · Paper page
  28. Yamaoka, 1981, A pharmacokinetics analysis program for microcomputer, J Pharm Dyn, 4, 879, 10.1248/bpb1978.4.879 · DOI · Paper page
  29. Cummins, 2002, Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4, J Pharmacol Exp Ther, 300, 1036, 10.1124/jpet.300.3.1036 · DOI · Paper page
  30. Wolozin, 2000, Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors, Arch Neurol, 10, 1439, 10.1001/archneur.57.10.1439 · DOI · Paper page
  31. Mason, 2005, A rationale for combined therapy with a calcium channel blocker and a statin: evaluation of basic and clinical evidence, Curr Drug Targets Cardiovasc Haematol Disord, 5, 489, 10.2174/156800605774962112 · DOI
  32. Kelly, 1999, Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4, Eur J Drug Metab Pharmacokinet, 24, 321, 10.1007/BF03190040 · DOI
  33. Lewis, 1996, Cytochrome P450. Substrate specificity and metabolism, 122
  34. Cao, 2006, Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model, Pharm Res, 23, 1675, 10.1007/s11095-006-9041-2 · DOI · Paper page
  35. Zhang, 1998, Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor, Drug Metab Dispos, 26, 360
  36. Hong, 2007, Effect of atorvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats, Arch Pharm Res, 30, 90, 10.1007/BF02977783 · DOI
  37. Cho, 2009, Effect of hesperidin on the oral pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats, J Pharm Pharmacol, 61, 825, 10.1211/jpp.61.06.0017 · DOI
  38. Hong, 2008, Effects of resveratrol on the pharmacokinetics of diltiazem and its major metabolite, desacetyldiltiazem, in rats, Cardiovasc Ther, 26, 269, 10.1111/j.1755-5922.2008.00060.x · DOI

Cited by

Metadata

Authors
Hong, S.-P., Yang, J.-S., Han, J.-Y., Ha, S.-I., Chung, J.-W., Koh, Y.-Y., Chang, K.-S., & Choi, D.-H.
Venue
Journal of Pharmacy and Pharmacology
Publisher
Oxford University Press (OUP)
Published
2011-01-01
Volume
63
Issue
1
Pages
129-135
ISSN
  • 2042-7158
  • 0022-3573
DOI
10.1111/j.2042-7158.2010.01160.x
Cited by
8
References
1
Language
en
Licence
academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.